Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Ovarian Cancer – Current Treatment – Current Treatment: Physician Insights – Ovarian Cancer (US)

Login to access report north_east
Contact sales account_box

Although chemotherapy has traditionally been the cornerstone of ovarian cancer treatment, angiogenesis and PARP inhibitors have revolutionized the treatment landscape, impacting prescribing decisions. The use of Lynparza (AstraZeneca / Merck & Co.), Zejula (GlaxoSmithKline), and Rubraca (Pharma&) as maintenance therapy across multiple lines and biomarker-defined patient populations is creating new sequencing dynamics. Elahere, set to be the standard of care for FRα-positive patients, is having an impact on the treatment algorithm for platinum-resistant disease.

Questions answered

  • What is the patient share of key therapies for advanced-stage ovarian cancer by line of therapy?
  • What factors influence physicians’ choice of first-line maintenance treatment (e.g., Lynparza plus bevacizumab versus Zejula) for advanced-stage ovarian cancer?
  • What are the key drivers of and barriers to the use of select drugs for advanced-stage ovarian cancer?
  • How do drug-treatment rates vary between key ovarian cancer patient populations, according to stage of disease and line of therapy?

Markets covered: United States

Primary research: Survey of 100 U.S. medical oncologists fielded in April 2024

Key drugs: bevacizumab, Lynparza, Zejula, Rubraca, and Elahere

Product description

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Table of contents

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Psoriatic Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Psoriatic Arthritis (US)
Treatment of psoriatic arthritis (PsA) typically begins with conventional disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, and progresses to more potent biologics and/or…
north_east
Report
Peripheral Arterial Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Peripheral Artery Disease (US)
Peripheral artery disease (PAD) is a subtype of atherosclerotic cardiovascular disease affecting the arteries of the lower extremities and is associated with reduced walking capacity, claudication…
north_east
Report
Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms: Claims Data Analysis – IBS-Constipation (including IBS without Diarrhea) (US)
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by altered bowel motility, stool consistency, and frequency, and is classified into constipation-predominant,…
north_east
Report
Biomarkers in Oncology – Access & Reimbursement – Access & Reimbursement – Biomarkers in Oncology – Biomarker-Driven Prescribing in NSCLC, Colorectal Cancer, Breast Cancer (US)
The increasing focus on biomarkers has reshaped the treatment paradigm in oncology, allowing physicians to tailor treatments to subpopulations of patients diagnosed with breast cancer, NSCLC and…
north_east
Report
Spinal Muscular Atrophy – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Spinal muscular atrophy (SMA) is a neuromuscular disease characterized by progressive muscle weakness and is a leading genetic cause of death in infants. SMA is divided into four clinical subtypes…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east